# Zepbound vs. Wegovy: Which GLP-1 Drug Is Best for Weight Loss?
Two GLP-1 receptor agonist medications dominate the weight loss conversation right now. Zepbound and Wegovy both use the active ingredient semaglutide, but they carry different FDA approvals and price tags.
Wegovy received FDA approval in 2021 specifically for weight management in adults with obesity or overweight conditions plus at least one weight-related health problem. Zepbound, also semaglutide, gained approval in 2023 for the same indication. The medications work identically, triggering hormones that reduce hunger and increase fullness signals.
The practical differences lie in insurance coverage and cost. Wegovy targets weight loss directly. Zepbound targets weight loss too, but doctors sometimes prescribe it off-label for other uses. Insurance companies treat them differently. Wegovy often qualifies for insurance coverage when medically necessary, while Zepbound's coverage varies by plan. Without insurance, both cost roughly $900 to $1,500 monthly.
Both medications produce similar weight loss results. Clinical trials show patients lose 15 to 22 percent of body weight over 68 weeks with either drug. Side effects overlap too: nausea, vomiting, diarrhea, and constipation appear most commonly, especially when starting or increasing doses.
The choice between them often depends on your insurance situation rather than effectiveness. Talk with your doctor about which medication your plan covers. Some patients respond better to one than the other, though the reasons remain unclear.
These drugs require ongoing injections, typically once weekly. Stopping either medication causes weight regain in most people. Patients should expect lifelong treatment if they want sustained results. The medications work best alongside diet and exercise changes, not as standalone